I.V. Babkina, Yu.S. Timofeev, E.A. Ten, D.V. Rogozin, Yu.N. Soloviev, E.Yu. Russo, Z.G. Kadagidze
N.N. Blokhin Russian Cancer Research Center, Kashirskoe shosse, 24, Moscow, Russian Federation, 115478

Introduction. Progress in the treatment of cancer and bone tumors including, is associated with a significant breakthrough in molecular biology, immunology, understanding the causes of the emergence of the tumor cell, patterns of the development and course of the tumor process. The aim of the study. The study of the levels of interleukin (IL) 16 in the serum of patients with bone tumors prior to treatment with a particular account of the histological structure of the tumor and late fate of the treatment Methods. Immunoassay. Results. The detection rate of IL16 in serum of the patients with bone tumors was 93%, no significant differences in levels of IL16 if considering the histological structure of tumor and stage malignant tumors were found. No relationship between the size of the primary tumor and the content of IL16 in serum was revealed. Differences in survivability rates of patients with regard to the content in the IL16 serum levels were determined before the beginning of a particular treatment. Overall 5-year survival value of osteosarcoma patients with the content of IL16 in serum >33,0 pg/ml was 1,6 times, with Ewing's sarcoma – 1,7 times, while in chondrosarcoma – 1,8 times less than in patients with IL16 content in the blood serum
osteosarcoma, chondrosarcoma, Ewing's sarcoma, IL16